Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AIM ImmunoTech Inc.
Report date December 31, 2024 · Filed January 03, 2025
Section 16 reporting ended · disclosed 2025-01-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 388,729 |
Reported balance
After 2024-12-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-31 · Grant · Acquired 8,768 · Balance 388,729 F1: The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares acquired on the Transaction Date were issued in lieu of director compensation pursuant to the issuer's Cash Conservation Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2019 Filed Jun 18, 2019 17:20 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherCommon Stock | 711 | $5.35 | $3,803.85 |
DisclosureSEC source: 0001191434-19-000003 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,031 F1 · kind: Shares issued for 50 percent of Director's Fee for the first half of June, 2019. F2 · balance_after: Previous balance of the amount of securities owned was divided by 44 due to the 44/1 stock split which occurred on June 11, 2019. Read SEC document |
| June 03, 2019 Filed Jun 14, 2019 18:06 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherCommon Stock | 38,013 | $0.10 | $3,801.30 |
DisclosureSEC source: 0001702626-19-000001 · primary_doc.xml · nonDerivative · entry 4 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,096 F4 · kind: Shares issued for 50 percent of Director's Fee for the second half of May, 2019. Read SEC document |
| May 16, 2019 Filed Jun 14, 2019 18:06 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherCommon Stock | 25,342 | $0.15 | $3,801.30 |
DisclosureSEC source: 0001702626-19-000001 · primary_doc.xml · nonDerivative · entry 3 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,083 F3 · kind: Shares issued for 50 percent of Director's Fee for the first half of May, 2019. Read SEC document |
| May 08, 2019 Filed Jun 17, 2019 20:48 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000007 · primary_doc.xml · nonDerivative · entry 2 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Rights offering warrants using the cashless conversion feature, were converted into .70 number of shares. Read SEC document |
| May 06, 2019 Filed Jun 14, 2019 18:06 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherCommon Stock | 18,101 | $0.21 | $3,801.21 |
DisclosureSEC source: 0001702626-19-000001 · primary_doc.xml · nonDerivative · entry 2 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,741 F2 · kind: Shares issued for 50 percent of Director's Fee for the second half of April, 2019. Read SEC document |
| May 03, 2019 Filed Jun 14, 2019 18:06 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherCommon Stock | 27,152 | $0.14 | $3,801.28 |
DisclosureSEC source: 0001702626-19-000001 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,640 F1 · kind: Shares issued for 50 percent of Director's Fee for the first half of April, 2019. Read SEC document |
| March 25, 2019 Filed Jun 17, 2019 20:48 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 140,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000007 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the forty shares issued. Read SEC document |
| February 28, 2019 Filed Mar 13, 2019 18:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSubr Rights(to buy) · Derivative | 40 | $1,000.00 Strike: $1,000.00 | $40,000.00 |
DisclosureSEC source: 0001583701-19-000004 · primary_doc.xml · derivative · entry 3 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Pref Stk/Warrants · Not disclosed shares Expires 2019-03-05 F1 · derivative.underlying: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F2 · derivative.underlying: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · derivative.underlying_shares: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 28, 2019 Filed Mar 13, 2019 18:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherWarrants | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001583701-19-000004 · primary_doc.xml · nonDerivative · entry 2 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 F2 · security: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · shares: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · price: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 28, 2019 Filed Mar 13, 2019 18:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSeries B Convertible Preferred Stock | 40 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001583701-19-000004 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40 F1 · security: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · shares: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · price: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 shares of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 17:35 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 50,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001450324-19-000007 · primary_doc.xml · derivative · entry 2 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-28 F2 · security: This option is being issued to senior management for serving as Chair on committees in the year 2019. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 17:35 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 207,343 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001450324-19-000007 · primary_doc.xml · derivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,343 Underlying: Common Stock · 207,343 shares Expires 2029-01-28 F1 · security: This option is being issued to senior management for a voluntary 100% deferral of Director's fees. Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 16:27 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001613377-18-000038 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,488 F1 · kind: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 16:24 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 25,238 | $0.22 | $5,552.36 |
DisclosureSEC source: 0001702626-18-000005 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,988 Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 17:12 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 172,786 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000027 · primary_doc.xml · derivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,786 Underlying: Common Stock · 172,786 shares Expires 2028-10-17 F1 · security: This option is being issued to senior management for a voluntary 100% deferral of Director's fees. Read SEC document |
| July 24, 2018 Filed Jul 24, 2018 13:24 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 126,000 | $0.31 | $39,060.00 |
DisclosureSEC source: 0001702626-18-000004 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,750 Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 14:48 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 98,098 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001613377-18-000016 · primary_doc.xml · derivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,098 Underlying: Common Stock · 98,098 shares Expires 2028-07-18 F1 · security: This option is being issued to senior management for a voluntary 100% deferral of Directors Fees. Read SEC document |
| May 16, 2018 Filed May 18, 2018 15:56 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 100,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001613377-18-000010 · primary_doc.xml · derivative · entry 2 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-05-16 F2 · security: This option was awarded by the Board of Directors for serving as chairman of various committees. Read SEC document |
| May 16, 2018 Filed May 18, 2018 15:56 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 152,053 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001613377-18-000010 · primary_doc.xml · derivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,053 Underlying: Common Stock · 152,053 shares Expires 2028-05-16 F1 · security: This option is being issued to senior management for a voluntary 100% deferral of Directors fees. Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 10:37 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 100,000 | $0.32 | $32,000.00 |
DisclosureSEC source: 0001702626-18-000002 · primary_doc.xml · nonDerivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,750 Read SEC document |
| April 12, 2018 Filed Apr 19, 2018 19:22 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 100,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001465652-18-000007 · primary_doc.xml · derivative · entry 1 APPELROUTH STEWART · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-04-12 F1 · security: This option is being awarded by the Board of Directors. Read SEC document |
| February 13, 2018 Filed Mar 1, 2018 18:57 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 226,023 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001613377-18-000004 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,023 Underlying: Common Stock · 226,023 shares Expires 2028-02-13 F1 · security: This option is being issued by senior management in exchange for a voluntary 100% reduction in directors fees. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 18:07 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 29,757 | $0.26 Strike: $0.36 | $7,736.82 |
DisclosureSEC source: 0001613377-17-000043 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,757 Underlying: Common Stock · 29,757 shares Expires 2027-08-31 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 17:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 25,953 | $0.29 Strike: $0.41 | $7,526.37 |
DisclosureSEC source: 0001613377-17-000037 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,953 Underlying: Common Stock · 25,953 shares Expires 2027-08-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:46 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 25,284 | $0.30 Strike: $0.42 | $7,585.20 |
DisclosureSEC source: 0001613377-17-000032 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,284 Underlying: Common Stock · 25,284 shares Expires 2027-07-31 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| July 15, 2017 Filed Jul 17, 2017 20:54 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 22,047 | $0.34 Strike: $0.48 | $7,495.98 |
DisclosureSEC source: 0001613377-17-000026 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,047 Underlying: Common Stock · 22,047 shares Expires 2027-07-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 18:44 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 17,290 | $0.44 Strike: $0.49 | $7,607.60 |
DisclosureSEC source: 0001613377-17-000020 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,290 Underlying: Common Stock · 17,290 shares Expires 2027-06-30 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in Director's fees. Read SEC document |
| June 15, 2017 Filed Jun 26, 2017 20:52 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 17,287 | $0.44 Strike: $0.49 | $7,606.28 |
DisclosureSEC source: 0001191434-17-000002 · primary_doc.xml · derivative · entry 4 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 Underlying: Common Stock · 17,287 shares Expires 2027-06-15 F1 · security: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| June 15, 2017 Filed Jun 26, 2017 15:09 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 17,287 | $0.44 Strike: $0.49 | $7,606.28 |
DisclosureSEC source: 0001702626-17-000003 · primary_doc.xml · derivative · entry 4 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 Underlying: Common Stock · 17,287 shares Expires 2027-06-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in salary. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in salary. Read SEC document |
| May 31, 2017 Filed Jun 26, 2017 20:52 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,361 | $0.53 Strike: $0.59 | $7,611.33 |
DisclosureSEC source: 0001191434-17-000002 · primary_doc.xml · derivative · entry 3 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,361 Underlying: Common Stock · 14,361 shares Expires 2027-05-31 F1 · security: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| May 31, 2017 Filed Jun 26, 2017 15:09 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,361 | $0.53 Strike: $0.59 | $7,611.33 |
DisclosureSEC source: 0001702626-17-000003 · primary_doc.xml · derivative · entry 3 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,361 Underlying: Common Stock · 14,361 shares Expires 2027-05-31 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in salary. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in salary. Read SEC document |
| May 15, 2017 Filed Jun 26, 2017 20:52 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 13,238 | $0.57 Strike: $0.64 | $7,545.66 |
DisclosureSEC source: 0001191434-17-000002 · primary_doc.xml · derivative · entry 2 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,238 Underlying: Common Stock · 13,238 shares Expires 2027-05-15 F1 · security: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| May 15, 2017 Filed Jun 26, 2017 15:09 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 13,238 | $0.57 Strike: $0.64 | $7,545.66 |
DisclosureSEC source: 0001702626-17-000003 · primary_doc.xml · derivative · entry 2 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,238 Underlying: Common Stock · 13,238 shares Expires 2027-05-15 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in salary. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in salary. Read SEC document |
| April 30, 2017 Filed Jun 26, 2017 20:52 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 12,644 | $0.60 Strike: $0.67 | $7,586.40 |
DisclosureSEC source: 0001191434-17-000002 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,644 Underlying: Common Stock · 12,644 shares Expires 2027-04-30 F1 · security: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. F1 · price: Correction to footnote from original filing on 6/26/17: This option is being issued in exchange for a voluntary 100% reduction in Director's Fees. Read SEC document |
| April 30, 2017 Filed Jun 26, 2017 15:09 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 12,644 | $0.60 Strike: $0.67 | $7,586.40 |
DisclosureSEC source: 0001702626-17-000003 · primary_doc.xml · derivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,644 Underlying: Common Stock · 12,644 shares Expires 2027-04-30 F1 · security: This option is being issued in exchange for a voluntary 100% reduction in salary. F1 · price: This option is being issued in exchange for a voluntary 100% reduction in salary. Read SEC document |
| August 24, 2016 Filed Mar 31, 2017 18:43 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 15,750 | $2.21 | $34,807.50 |
DisclosureSEC source: 0001702626-17-000002 · primary_doc.xml · nonDerivative · entry 1 Appelrouth Stewart · CIK 0001702626 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 F1 · shares: Shares and prices have been adjusted to give retroactive effect to the 1 for 12 reverse stock split effected on 8/29/16. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.16 to $2.22. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.